Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

abnobaVISCUM 900

Phase 3Small molecule

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Superficial Bladder CancerActive, not recruiting

Superficial Bladder CancerPhase 3

Active, not recruiting

Timeline

Expected Milestones

Q4 2028

Phase 3Active, not recruiting

Study completion

NCT02106572

Clinical

Trials by Indication[1]

Bladder Cancer1 trial

Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer

Completed·AAbnoba Gmbh·Phase 1/2·NCT02007005·37 enrolled

Unspecified1 trial

Therapeutic Instillation of Mistletoe

Active, not recruiting·AAbnoba Gmbh·Phase 3·NCT02106572·548 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for abnobaVISCUM 900. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — abnobaVISCUM 900 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for abnobaVISCUM 900. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Abnoba Gmbh company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAbnoba Gmbh

Related News